Outcome of Photodynamic Therapy for Early Esophageal Cancer.
- Author:
Young Koog CHEON
1
;
Wan Jung KIM
;
Joo Young CHO
;
Joon Seong LEE
;
Moon Sung LEE
;
Chan Sup SHIM
Author Information
1. Department of Internal Medicine, Institute for Digestive Research, Soon Chun Hyang University College of Medicine, Seoul, Korea. yksky001@hanmail.net
- Publication Type:Original Article
- Keywords:
Photodynamic therapy;
Endoscopic treatment;
Early esophageal cancer;
Hematoporphyrin
- MeSH:
Biopsy;
Disulfiram;
Endosonography;
Esophageal Neoplasms*;
Follow-Up Studies;
Gastroscopy;
Hematoporphyrin Derivative;
Hematoporphyrins;
Humans;
Karnofsky Performance Status;
Lymph Nodes;
Male;
Neoplasm Metastasis;
Photochemotherapy*;
Quality of Life;
Recurrence
- From:Gut and Liver
2007;1(2):126-131
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Endoscopic treatment as an alternative to surgery has become increasingly popular for improving the quality of life. Although photodynamic therapy (PDT) has been used for the endoscopic treatment of digestive cancer, its curative efficacy remains unclear. We evaluated the curative efficacy of PDT in superficial esophageal cancer in inoperable patients. METHODS: Ten male patients with histologically proven early esophageal cancer (surgery was contraindicated for age > 80 years, surgery was contraindicated, Karnofsky performance status of at least 30%, or refusal of surgery) were intravenously injected with a hematoporphyrin derivative (2 mg/kg), and PDT was performed 48 h later. The response to treatment was assessed by gastroscopy with biopsies. RESULTS: The mean follow-up period was 27.6 months (range, 9.6-58.7 months). Endoscopic ultrasonography revealed that all ten cases were at tumor stage T1. Complete remission (CR) to initial and subsequent PDT was observed in all patients. For the CR cases, the recurrence rate was 10% (1/10) and the time from initial PDT to recurrence was 9.6 months. CONCLUSIONS: For patients in whom surgery is risky or refused, PDT may represent an acceptable alternative treatment modality, especially for superficial esophageal cancer without lymph node metastasis. However, a study involving long-term follow-up in a large population is needed for confirmation.
